CNRS Technologies

Find the best CNRS technologies to boost your innovative project.

Newest patents

You are a research scientist?

We can guide you through the whole technology transfer process.

See all our services

You are a corporate player?

Thanks to our expertise, our network and our know-how of the innovation ecosystem, we support you throughout your project.

Contact us

Follow our news and upcoming events

Discover CNRS technologies

Meet our team

Close

Phosphole derivatives complexed with metals, and pharmaceutical uses thereof

Reference

86508-01

Patents status

French patent application FR0408427 filed on July 20th, 2004 and entitled “Dérivés phospholes complexés à des métaux et leurs utilisations pharmaceutiques”.

Inventors

Elisabeth DAVIOU-CHARVET
Katja BECLER-BRANDENBURG
Valérie DEBORDE
Régis REAU
Heiner SCHIRMER
Christel HEROLD-MENDE

commercial status

Exclusive or non-exclusive licenses

Laboratory

Interdisciplinary Research Center, Giessen University, Germany
Biochemie-Zentrum, Heidelberg University, Germany
Department of Neurosurgery, Heidelberg University, Germany
UMR 6509, CNRS / Rennes 1 University, France.

Description

TECHNICAL DESCRIPTION

This invention describes pharmaceutical compositions containing phosphole derivatives complexed with gold or platinium and their use in particular for the prevention or treatment of pathologies associated with an excess activity of human glutathione reductase and/or thioredoxin reductase. These components act as irreversible inhibitors of glutathione and thioredoxin reductases.

INDUSTRIAL APPLICATIONS

– Prevention or treatment of cancers, rheumatoid polyarthritis, psoriasis or Sögren syndrome.
– Prevention or treatment of resistance to anti-cancerous drugs.

The anti-tumour activity of this pharmaceutical composition was tested in vivo on rat and showed a 44% reduction of the tumour size.

For further information, please contact us (Ref 86508-01)

Need further information ?

Contact us
Close

Contact us

  • This field is for validation purposes and should be left unchanged.
Close

Newest patents